The positive results from the Phase 2 trial of Dazodalibep in Sjögren's Syndrome indicate that Horizon Therapeutics is making progress in developing a new treatment option for the autoimmune disease. This could potentially lead to increased revenues and a positive impact on the company's stock price in the short term.